Severe COVID-19 disease is closely related with dysregulation of local and systemic immune responses. Thus, since the beginning of the pandemic at the end of 2019, various clinical treatments have been used seeking to i) alleviate the symptoms of patients with severe COVID-19 and ii) save the lives of those patients in critical condition hospitalized in intensive care units, being one of the most successful, the application of immunomodulators such as Baricitinib and Ruxolitinib, which act on the signaling networks associated with the JAK/STAT complex, here considered as a strategy to improve the performance and management of traffic in the JAK/STAT signaling network, and which have proven to be effective in the treatment of cytokine storm syndrome, common in patients with severe COVID-19 [10, 11].

The underlying logic of this clinical strategy can be represented, in a general way (Figure 1), as the action of two associated balanced processes, the first to the control of the state of hyper inflammation due to the cytokine storm syndrome, by the administration of the regulator, and the second, associated with viremia control given the clinical improvement of the patient.

Recent advances in the pathophysiology of the SARS-CoV-2 infection have indicated these patients might experience a cytokine release syndrome (CRS), characterized by increased interleukin-6 (IL-6), IL-2, IL-7 and IL-10 levels among others [12]. Therefore, the treatment of cytokine storm has been proposed as a critical part of rescuing severe COVID-19. The mechanism of immunoregulation of hyperinflammation by intervening in the JAK/STAT system (Figure 2), is represented by a CLD with a reinforcing cycle (R1) and six balance cycles (B1–B6), which are carried out in the cytoplasm and into the nucleus of the cell, illustrating the complexity of the process and explaining why sometimes, there are contradictory results of these therapies in COVID-19. The dominance of the reinforcing loop (R1) (Figure 2), indicates a critical role in this initial step of the immunomodulators treatment which can be illustrated by the fact that immune cells constantly patrol the body via the bloodstream, and migrate into multiple tissues where they face variable and sometimes demanding environmental conditions. Nutrient and oxygen availability can vary during homeostasis, and especially during an immune response, creating fine-tuning conditions determining the fate of the treatment in each patient, enhancing the necessity to perform sensitive tests to quantitatively measure JAK-STAT1/2 and JAK-STAT3 signaling pathway activity in immune cells and blood samples, which can contribute to solutions for the COVID-19 crisis in severe patients [13, 14].

Caching data is a process that stores multiple copies of data or files in a temporary storage location—or cache—so they can be accessed faster, which corresponds in our model, to the activation of innate immunity and its associated trained immunity. In humans, after the skin, the innate component (e.g., epithelial and phagocytic cell enzymes, phagocytes, inflammation-related serum proteins, surface and phagocyte granule antimicrobial peptides) of the immune system is, without a doubt, one of the most effective mechanisms for the control of pathogenic microorganisms [15]. The case of the coronavirus is not the exception either, since more than 80% of those infected with the SARS-CoV-2 virus do not develop the disease or present mild symptoms, a fact that is attributed to the adequate action of the innate immune response mechanisms [16, 17]; which is why, from the perspective of NetOps, the induction of these mechanisms is an object of basic and clinical research of primary importance.

Also related to immune data-caching, recent epidemiological studies have shown that, in addition to disease-specific effects, vaccines against infectious diseases have nonspecific effects on the ability of the immune system to handle other pathogens; for example, there is evidence in animal models that an initial infection or vaccination with bacteria (for example, BCG) protects athymic nude mice against a lethal infection with Candida albicans [18]. Moreover, the increased susceptibility to severe disease in the elderly and individuals with co-morbidities (risk factors) argues for an initial defect in anti-viral host defense mechanisms; therefore, the long-term boosting of innate immune responses could induce heterologous protection against infections in these patients [19, 20] (Figure 3).

Regarding a healthy lifestyle, recent research indicated that optimizing vitamin D blood levels could offer a solution approach that promises a heavily reduced fatality rate as well as solving the public health problem of counteracting the general vitamin D deficiency [21]. On the other hand, taking into account risk factors, an overwhelming preponderance of cases and deaths is observed within the elderly population, especially in those with pre-existing conditions and comorbidities. Immunosenescence and inflamm-aging are considered key features of the aging immune system wherein accumulation of senescent immune cells contributes to its decline and simultaneously, increased inflammatory phenotypes cause immune dysfunction.

On the other hand, a challenge with specific microbial stimuli induces long-lasting epigenetic changes in innate immune cells that result in their enhanced response to a second challenge by the same or unrelated microbial insult, a process referred to as trained immunity. This opens a new avenue in vaccinology to develop TIbV, defined as vaccine formulations that induce training in innate immune cells [22].

In IT, data compression is the process of encoding, restructuring, or otherwise modifying data, to reduce its size. This process can be equated, in immunology, with one of the most outstanding aspects of the specific or adaptive immune response, which is the development of immunological memory mechanisms, and without a doubt, effective vaccines are a major operator in these immune NetOps. Significant advances in cutting-edge vaccine technologies over the past decade have resulted in two main types of SARS-CoV-2 vaccines now being approved for emergency use, an unprecedented achievement in modern medical science. The approved vaccines developed by Pfizer and Moderna use mRNA technology and lipid nanoparticle (LNP) delivery systems, while the approved formulations by AstraZeneca, and Johnson & Johnson, contain DNA delivered within non-replicating recombinant adenovirus (AdV) vector systems [23]. Immune data compression by vaccination occurs through two mechanisms (Figure 4). First, in modern immunology it is a well-known fact that effective DNA, RNA, recombinant, and particulate vaccines are made to recognize, not a huge number of antigens of the pathogen but, a relatively small set of antigenic determinants, as the spike protein of coronavirus, conferring long term neutralizing immunity against SARS-CoV-2 through the second impressive compression mechanism, the establishment of a lineage of specific memory B and T cells.

When vaccination against smallpox was introduced around 200 years ago, positive side effects such as protection against measles, scarlet fever, and whooping cough, among others, were noticed [24]. These and many other clinical observations pointed to a long-lasting non-specific collateral benefit associated with these vaccines, regardless of specific priming and subsequent clonal selection of T and B lymphocytes specific for the nominal antigens present in the vaccine [25–27]. Considering that IT buffer tuning consists in operating the network to construct the smallest information unit for effective communication between subtasks, immunologists shortly could use a strategy based on the implementation of the concurrent activation of innate and adaptative immune responses to obtain an immunocompetent state in vaccinated individuals designing a new type of biologicals, for example, TIbV, to confer long-lasting protection with a “buffer” capacity, not only by collateral benefits against other pathogens but generating durable patterns of adaptative immune responses, induced by the multiple-function vaccines (M-vaccines), which stimulates the innate immune compartment in the host (Figure 5) and thereafter, the specific immune compartment.